文献速递胸部肿瘤放疗放疗物理与技术

基于每日CBCT的剂量计算提升肺癌放疗剂量递增的安全性

Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy.
PubMed 文献 · Radiother Oncol · 2024-08-26

本研究在NARLAL2剂量递增试验中,对21例局部晚期非小细胞肺癌患者利用每日CBCT重新计算并累积实际递送剂量。标准治疗中计划适应使CTV-T低剂量患者数从6例降至1例,递增治疗中从5例降至0例;递增治疗有3例患者分次超出心脏、支气管或食管限制,1例累积心脏剂量超限。结论认为每日影像引导和自适应放疗下剂量递增对多数患者剂量学安全。

要点

  • 标准治疗中计划适应使CTV-T低剂量患者数从6例降至1例,低剂量分次数从161次降至56次。
  • 递增治疗中计划适应使CTV-T低剂量患者数从5例降至0例,低剂量分次数从81次降至11次。
  • 递增治疗有3例患者分次超出心脏、支气管或食管限制,1例累积心脏剂量超限。

核心结论

  • 对于局部晚期非小细胞肺癌患者,使用每日影像引导和自适应放疗进行剂量递增对多数患者是剂量学安全的。
  • 基于每日CBCT的剂量计算是监测靶区覆盖和危及器官剂量的有效工具。

研究设计与样本

  • 本研究为斯堪的纳维亚III期剂量递增试验(NARLAL2)的一部分,评估21例局部晚期非小细胞肺癌患者的递送剂量。
  • 患者随机接受标准或递增异质性剂量递送,两种治疗计划均在随机化前制定并批准。
  • 每日锥形束CT(CBCT)用于患者定位,自适应放疗为强制要求。
  • 标准与递增计划(包括自适应再计划)在每例患者每日CBCT上重新计算,并累积至计划CT上。
  • 评估累积剂量和每个治疗分次缩放至全疗程后靶区与危及器官剂量及计划适应的影响。

主要发现

  • 标准治疗中,计划适应使CTV-T低剂量患者数从6例降至1例,低剂量分次数从161次降至56次。
  • 递增治疗中,计划适应使CTV-T低剂量患者数从5例降至0例,低剂量分次数从81次降至11次。
  • 剂量递增中,3例患者分次超出心脏、支气管或食管限制,1例累积心脏剂量超限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dose-escalation in lung cancer comes with a high risk of severe toxicity. This study aimed to calculate the delivered dose in a Scandinavian phase-III dose-escalation trial. METHODS: The delivered dose was evaluated for 21 locally-advanced non-small cell lung cancer (LA-NSCLC) patients treated as part of the NARLAL2 dose-escalation trial. The patients were randomized between standard and escalated heterogeneous dose-delivery. Both treatment plans were created and approved before randomization. Daily cone-beam CT (CBCT) for patient positioning, and adaptive radiotherapy were mandatory. Standard and escalated plans, including adaptive re-plans, were recalculated on each daily CBCT and accumulated on the planning CT for each patient. Dose to the clinical target volume (CTV), organs at risk (OAR), and the effects of plan adaptions were evaluated for the accumulated dose and on each treated fraction scaled to full treatment. RESULTS: For the standard treatment, plan adaptations reduced the number of patients with CTV-T underdosage from six to one, and the total number of fractions with CTV-T underdosage from 161 to 56; while for the escalated treatment, the number of patients was reduced from five to zero and number of fractions from 81 to 11. For dose-escalation, three patients had fractions exceeding trial constraints for heart, bronchi, or esophagus, and one had an accumulated heart dose above the constraints. CONCLUSION: Dose-escalation for LA-NSCLC patients, using daily image guidance and adaptive radiotherapy, is dosimetrically safe for the majority of patients. Dose calculation on daily CBCTs is an efficient tool to monitor target coverage and OAR doses.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Thomsen SN, Møller DS, Knap MM, et al. Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy. Radiother Oncol. 2024. PMID: 39197502. doi:10.1016/j.radonc.2024.110506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。